Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment

Schizophrenia Research

Volumn 50, Issue 1-2, 2001, Pages 41-53

  Knott, V ^a   Labelle, A ^a   Jones, B ^b   Mahoney, C ^a  

^a ROYAL OTTAWA HOSPITAL   (Canada)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Clozapine; Electroencephalography; Global psychopathology; Positive and negative symptoms; Schizophrenia

Indexed keywords

CLOZAPINE;

ADULT; AGED; ALPHA RHYTHM; ARTICLE; BETA RHYTHM; BRAIN REGION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELTA RHYTHM; DIAGNOSTIC VALUE; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; THETA RHYTHM; TOPOGRAPHY; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BRAIN MAPPING; CLOZAPINE; DRUG ADMINISTRATION SCHEDULE; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 0035972618     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(00)00165-1     Document Type: Article

References (100)

1. Quantitative EEG in Schizophrenic patients before and during pharmacotherapy
2. The comparative efficacy and long term effect of clozapine treatment on neuropsychological test performance
3. New methods to determine the CNS effects of antigeriatric compounds: EEG topography and glucose use
4. General pharmacology of clozapine
5. Pretreatment EEG predicts short-term response to haloperidol treatment
6. Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve
7. Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients
8. EEG as an outcome measurement in treatment with antipsychotic psycho pharmacea
9. Theoretical and practical importance of plasma levels of haloperidol correlations with clinical and computerized EEG data
10. Physical aspects of the EEG in schizophrenics
11. Intra and inter-hemispheric changes in alpha intensities in EEGs of schizophrenic patients versus matched controls
12. Intra-and interhemispheric EEG differences quantified by spectral analysis: Comparative study of two groups of schizophrenics and a control group
13. EEG activation patterns during the performance of tasks involving different components of mental calculation
14. EEG profile studies of clozapine in volunteers and psychiatric patients
15. Clozapine: A review of its pharmacological properties, and therapeutic use in schizophrenia
16. Central dynamics, laterality and psychopathology: A commentary
17. Studies in EEG power and coherence (8-13 Hz) in depression mania and schizophrenia compared to controls
18. Spontaneous motor activity in healthy volunteers after single doses of haloperidol
19. Pharmacologic strategies for augmenting cognitive performance in schizophrenia
20. Topographical distribution of absolute alpha-power in the EEG and psychopathology in schizophrenic outpatients
21. C-EEG brain mapping in DSM-III schizophrenics after acute and chronic haloperidol treatment
22. EEG mapping in drug-free schizophrenics: Differences from healthy subjects and changes induced by haloperidol treatment
23. QEEG alpha 1 changes after a single dose of high potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients
24. Multilead quantitative EEG profile of clozapine in resting and vigilance-controlled conditions
25. Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs
26. Schizophrenia and EEG spectral analysis
27. The effects of clozapine on cognition and psychiatric symptoms in patients with schizophrenia
28. Effects of ICI 169, 369, a selective serotonin 2 antagonist in electrophysiological tests predictive of antipsychotic activity
29. EEG mapping of left hemisphere dysfunction during motor performance in schizophrenia
30. Bilateral brain dysfunction during motor activities in type II schizophrenia measured by EEG mapping
31. EEG alterations and seizures during treatment with clozapine: A retrospective study of 283 patients
32. Improvement in cognitive function and psychiatric symptoms in schizophrenic patients receiving clozapine
33. EEG alterations in patients with clozapine in relation to plasma levels
34. Development of a classification rule for four clinical therapeutic psychotropic drug classes with EEG power spectrum variables of human volunteers
35. The effect of clozapine on symptom reduction, neurocognitive function and clinical management in treatment refractory state hospital schizophrenic inpatients
36. Qualitative and quantitative EEG findings in schizophrenia
37. Computer-analyzed electroencephalogram to predict the therapeutic outcome in schizophrenia
38. Quantitative EEG brain mapping in psychotropic drug development, drug treatment selection, and monitoring
39. Quantitative EEG changes during thiothixene treatment of chronic schizophrenics
40. EEG findings in chronic schizophrenics based on digital computer period analysis and analog power spectra
41. Computerized EEG predictor of outcome in schizophrenia
42. HZI systems for EEG parametization and classification of psychotropic drugs
43. Computerized EEG as a predictor of drug response in treatment resistant schizophrenics
44. The E-adjustment procedure for repeated measures analyses of variance
45. Clozapine increases EEG photic driving in clinical responders
46. Topographic analysis of EEG photic driving in patients with schizophrenia following clozapine treatment
47. Normative data banks and neurometrics: Basic concepts, methods and results of norm constructions
48. Quantitative electrophysiological characteristics and subtyping of schizophrenia
49. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
50. Computed electroencephalographic activity mapping in schizophrenia
51. Alpha frequency in schizophrenia: An association with enlarged cerebral ventricles
52. Reliability and validity of the positive and negative syndrome scale in schizophrenia
53. The positive and negative syndrome scale (PANSS): Rationale and standardization
54. Computerized EEG topography findings in schizophrenic patients before and after haloperidol treatment
55. The EEG in schizophrenia
56. EEG correlates of acute nicotinic and muscarinic cholinergic blockade: Separate and combined administration of scopolamine and mecamylamine in normal human subjects
57. Acute effect of tryptophan depletion and enfluramine on quantitative EEG and mood in healthy male subjects
58. Paroxysmal EEG activity and psychopharmacology during the treatment with clozapine
59. A psychological model of the pathogenesis of schizophrenic symptoms
60. Drug induced paroxysmal EEG activities
61. Effects of granisetron and haloperidol, alone and in combination, on psychometric performance and the EEG
62. Saccadic-eye movements in tracking, fixation, and rest in schizophrenic and normal subjects
63. A preliminary attempt to relate individual differences in EEG test dose response to clinical effect
64. A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiside in normal volunteers
65. Negative symptoms and EEG alpha activity in schizophrenic patients
66. EEG asymmetry in schizophrenic patients before and during neuroleptic treatment
67. EEG coherence in unmedicated schizophrenic patients
68. Localization of sources of brain alpha/theta activity and influence of the mode spontaneous mentation
69. Computerized EEG in schizophrenic patients
70. Structure and function: Brain electrical activity mapping and computed tomography in schizophrenia
71. Brain electrical activity mapping (BEAM) in schizophrenic patients
72. Altered topography of EEG spectral content in schizophrenia
73. Computed EEG in schizophrenics
74. EEG coherence in unmedicated schizophrenic patients: Topographical study of predominantly never medicated cases
75. Quantitative EEG: II. Frequency analysis and topographic mapping in clinical settings
76. QEEG profiles of psychiatric disorders
77. Cognitive improvement in schizophrenia with novel antipsychotic medications
78. Pathophysiology of schizophrenia and the role of newer antipsychotics
79. EEG profile and behavioral changes after a single dose of clozapine in normals and schizophrenics
80. Computer analyzed EEG and behavioral changes after psychoactive drugs
81. The use of pharmaco-EEG in drug profiling
82. Determination of pharmacodynamics of the new neuroleptic zetidoline by neuroendocrinologic, pharmaco-EEG, and psychometric studies - Part 1
83. Quantitative, E.E.G., 1986. SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy
84. Comparative placebo-controlled pharmaco-dynamic studies with zoterpine and clozapine utilizing pharmaco-EEG and psychometry
85. EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms: Comparative studies with remoxipride/haloperidol
86. EEG-brain mapping: A method to optimize therapy in schizophrenics using absolute power and center frequency values
87. Quantitative EEG and BPRS data following haldol-diaconate administration in schizophrenics
88. A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia
89. EEG in schizophrenia
90. Computerized EEG profiles of haloperidol, chlorpromazine, clozapine and placebo in treatment resistant schizophrenia
91. Eye blink and schizophrenia: Psychosis or tardive dyskinesia?
92. EEG abnormalities associated with clozapine treatment
93. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition
94. Background EEG reactivity in auditory event-related potentials
95. Cerebral activity and behavior: Control by central cholinergic and serotonergic systems
96. Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: A cross-sectional study
97. Clozapine-induced seizures and EEG changes
98. Slower theta activity over the midfrontal cortex in schizophrenic patients
99. The effects of haloperidol on the EEG spectrum
100. Frontal spectral EEG findings in acutely ill schizophrenics